title: MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy.
abstract: OBJECTIVE
  The aim of this study was to evaluate the prevalence of cancer testis tumor-associated antigens MAGE-A and NY-ESO-1 in cervical cancer and correlate expression patterns with clinicopathologic parameters and prognosis.
  
  
  METHODS
  One hundred sixty-two cervical cancer samples from 109 patients who were treated with radical hysterectomy, neoadjuvant chemotherapy, or pelvic disease recurrence were analyzed by immunohistochemistry.
  
  
  RESULTS
  MAGE-A was expressed by 32/94 (34%) and 7/15 (47%) previously untreated and recurrent tumors, respectively. NY-ESO-1 was expressed by 46/94 (49%) and 6/15 (40%) previously untreated and recurrent tumors, respectively. MAGE-A in early stage tumors was correlated to tumor size and lymph node metastases (P = .024 and P = .046, respectively) whereas NY-ESO-1 to tumor grading (P = .039).
  
  
  CONCLUSIONS
  Cervical cancer frequently expresses cancer testis tumor-associated antigens. MAGE-A and NY-ESO-1 expression rates are not influenced by systemic therapies. Cancer testis tumor-associated antigens are correlated to common prognostic factors.
authors.affiliation: Department of Experimental Medicine, La Sapienza University, Rome, Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Napoletano
authors.forename: Filippo
authors.initials: F
authors.lastname: Bellati
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Tarquini
authors.forename: Federica
authors.initials: F
authors.lastname: Tomao
authors.forename: Federica
authors.initials: F
authors.lastname: Taurino
authors.forename: Giulio
authors.initials: G
authors.lastname: Spagnoli
authors.forename: Aurelia
authors.initials: A
authors.lastname: Rughetti
authors.forename: Ludovico
authors.initials: L
authors.lastname: Muzii
authors.forename: Marianna
authors.initials: M
authors.lastname: Nuti
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Benedetti Panici
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000235:genetics / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001707:Biopsy, Needle; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D007150:Immunohistochemistry; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D009367:Neoplasm Staging; D011336:Probability; D011379:Prognosis; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D046509:Tissue Culture Techniques; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C104948:CTAG1B protein, human; D008565:Membrane Proteins